Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville
2019年5月21日 - 1:55PM
- Curetis and EIB agree on equity-linked participation upon
maturity of new EUR 5 million tranche of debt financing - Yorkville
to provide funding of EUR 1.5 million to Curetis
Amsterdam, the Netherlands, and Holzgerlingen, Germany,
May 21, 2019 -- Curetis N.V. (the "Company" and, together
with Curetis GmbH, "Curetis"), a developer of next-level molecular
diagnostic solutions, today announced that Curetis will receive
another EUR 6.5 million in gross proceeds under two financing
facilities.
Firstly, under the EIB debt financing facility originally put in
place in December 2016, Curetis now stands to receive another EUR
5.0 million tranche of non-dilutive debt financing. This tranche
will also have a five-year term to maturity and will require
interest-only payments during that five-year term. In line with all
prior tranches, the majority of interest is also deferred into the
bullet repayment structure upon maturity. In return for EIB waiving
certain conditions precedent to disbursing this EUR 5 million
tranche, the parties have agreed on a 2.1% participation percentage
interest (PPI). Upon maturity of the tranche, i.e. not before
around mid-2024 (and no later than mid-2025), EIB will be entitled
to an additional payment that is equity-linked and equivalent to
2.1% of the then total valuation of Curetis. All other terms and
conditions of the EIB financing contract with Curetis remain
unchanged.
Secondly, under the up to EUR 20 million Yorkville convertible
notes financing facility that was originally implemented in October
2018, Curetis has now received access to another EUR 1.5 million
gross in funding subject to having received the aforementioned EUR
5 million tranche from EIB. Net proceeds from this tranche are
expected to be about EUR 1.36 million. As with the prior tranche,
Yorkville is expected from time to time to convert such notes into
equity and Curetis will then issue new shares. For further details
on the Yorkville convertible notes facility, please also see the
“Convertibles” section under:
https://curetis.com/investors/#corporate-governance
“We are pleased to see continued support and funding from both
EIB and Yorkville,” said Oliver Schacht, PhD, CEO of Curetis. “The
additional funding will allow Curetis to continue executing on its
R&D programs such as the Unyvero A30 RQ platform development
towards partnering, the Unyvero LRT for BAL specimen in the US, as
well as the Ares Genetics R&D programs. The Yorkville funding
will also support commercial activities in the US and business
development initiatives in Europe and Asia.”
About Curetis
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly owned subsidiary Ares Genetics
GmbH is developing next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
the presumably most comprehensive database worldwide on the
genetics of antimicrobial resistances, ARESdb, with advanced
bioinformatics and artificial intelligence.
For further information, please
visit www.curetis.com
and
www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to
buy nor an offer to subscribe for securities and neither this
document nor any part of it should form the basis of any investment
decision in Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons. This press release
includes statements that are, or may be deemed to be,
“forward-looking statements.” These forward-looking statements can
be identified by the use of forward-looking terminology, including
the terms “believes,” “estimates,” “anticipates,” “expects,”
“intends,” “targets,” “may,” “will,” or “should” and include
statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. Curetis’ actual results may differ materially from
those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Contact details
Curetis Max-Eyth-Str. 4271088 Holzgerlingen, GermanyTel. +49
7031 49195-10pr@curetis.com or ir@curetis.comwww.curetis.com
- www.unyvero.com
International Media & Investor
InquiriesakampionDr. Ludger Wess / Ines-Regina Buth
Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel. +49
30 23 63 27 68
- 20190521_Curetis_PR_EN_EIB-YV_final_approved
Direxion Daily Healthcar... (AMEX:CURE)
過去 株価チャート
から 1 2025 まで 2 2025
Direxion Daily Healthcar... (AMEX:CURE)
過去 株価チャート
から 2 2024 まで 2 2025